STOCK TITAN

Vera Therapeutics, Inc. - $VERA STOCK NEWS

Welcome to our dedicated page for Vera Therapeutics news (Ticker: $VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vera Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vera Therapeutics's position in the market.

Rhea-AI Summary

Vera Therapeutics has appointed Christy J. Oliger to its board of directors, effective June 7, 2024. Oliger brings over 30 years of experience in the biopharmaceutical industry, having led significant commercial product launches and built highly effective teams. She currently serves on the boards of Karyopharm Therapeutics, Replimune Group, and LAVA Therapeutics, and has past board experience with Sierra Oncology, Reata Pharmaceuticals, and RayzeBio. Oliger’s extensive experience will support Vera's advancement of atacicept for IgAN treatment and its potential commercial launch.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

On June 4, 2024, Vera Therapeutics granted inducement awards to five new employees under its 2024 Inducement Plan. These awards include non-qualified stock options to purchase 31,250 shares of Class A common stock and restricted stock units (RSUs) for 14,500 shares. The stock options have an exercise price of $39.47 per share, matching Vera’s closing price on that date. The stock options and RSUs vest over four years with specific conditions attached. These grants were approved by Vera's Compensation Committee in adherence to Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
Rhea-AI Summary

Vera Therapeutics, a late clinical-stage biotechnology company, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference.

The event will occur from June 10-13, 2024, at the Loews Miami Beach Hotel.

CEO Marshall Fordyce, M.D., will present on June 12 at 10:40 AM EDT, and the management team will engage in one-on-one investor meetings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
conferences
Rhea-AI Summary

Vera Therapeutics announced that the FDA has granted Breakthrough Therapy Designation to its drug atacicept for the treatment of Immunoglobulin A Nephropathy (IgAN). This decision is based on data from a Phase 2b ORIGIN trial, showing atacicept's potential to significantly improve kidney function as measured by eGFR over existing treatments. The company plans to release long-term results from this trial later in 2024 and expects Phase 3 trial results in the first half of 2025, which will support its regulatory approval submission.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
-
Rhea-AI Summary

Vera Therapeutics announced positive results from its Phase 2b ORIGIN trial of atacicept in treating IgA nephropathy (IgAN) at the 61st European Renal Association Congress. Over 72 weeks, atacicept showed stable kidney function, rapid, and sustained improvements in hematuria compared to placebo. The study revealed a 91% retention rate, enhancing the drug's safety profile. Additionally, atacicept led to significant reductions in Gd-IgA1, hematuria, and UPCR in participants. Vera aims to present 96-week data in Q4 2024 and expects Phase 3 enrollment completion by Q3 2024, with primary endpoint data by H1 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Vera Therapeutics, a biotechnology company, shared positive 72-week data from its Phase 2b ORIGIN clinical trial for IgAN. They reported no kidney function loss with atacicept treatment. They anticipate Phase 3 ORIGIN 3 trial results in 2025. The company completed a $287.5 million financing, strengthening its financial position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
Rhea-AI Summary

Vera Therapeutics, Inc. (Nasdaq: VERA) granted inducement awards to new employees under its 2024 Inducement Plan. The awards include non-qualified stock options and restricted stock units. The stock options have exercise prices based on Vera's closing trading prices on specific dates. The awards vest over four years, contingent on the employees' continued service with the company. These awards were approved as inducements under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
-
Rhea-AI Summary
Vera Therapeutics, Inc. announces the acceptance of 72-week data of atacicept in IgAN as a best-ranked abstract and the analysis of the impact of atacicept on hematuria in IgAN as a focused oral presentation at the 61st European Renal Association Congress. The Phase 2b ORIGIN clinical trial data will be presented virtually and in Stockholm from May 23—26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
none
-
Rhea-AI Summary
Vera Therapeutics, Inc. (VERA) presented positive 72-week data from the Phase 2b ORIGIN clinical trial for IgA Nephropathy (IgAN), showing no loss of kidney function. They are actively enrolling the pivotal Phase 3 ORIGIN 3 study for atacicept, expecting topline data in 1H 2025. The company completed a $287.5 million financing, strengthening their balance sheet and extending cash runway. Key fiscal year 2023 highlights include appointing industry veterans to key positions, presenting positive data from the ORIGIN trial, and advancing their pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
Rhea-AI Summary
Vera Therapeutics, Inc. (VERA) will participate in the 44th Annual TD Cowen Health Care Conference. The company's management team will discuss IgAN and hold a Fireside Chat. Investors can access the webcast and a replay of the event on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
conferences
Vera Therapeutics, Inc.

Nasdaq:VERA

VERA Rankings

VERA Stock Data

2.10B
39.88M
7.95%
85.25%
11.62%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
BRISBANE

About VERA

trucode gene repair is advancing its novel triplex gene editing platform to potentially cure devastating genetic diseases, with initial focus on sickle cell disease and cystic fibrosis. the elegance of triplex gene editing lies in its ability to harness natural, high-fidelity dna repair mechanisms, and its independence from the requirement for exogenous nucleases and viral vectors.